BMEA / Biomea Fusion, Inc. - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Biomea Fusion, Inc.

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits. (d) Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 05, 2025 Biomea Fusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40335 82-2520134 (State or other jurisdiction of incorporation) (Commission Fil

Form of indenture for subordinated debt securities and the related form of subordinated debt security

Exhibit 4.5 BIOMEA FUSION, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 3 Section 2.01 Designation and Terms of Securities. 3 Section 2.02 Form of Securities and Trustee’s Certificate

Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights • Three presentations at ADA 2025 highlighted the therapeutic potential of icovamenib across multiple aspects of metabolic health: • In patients with type 2 diabetes

Exhibit 99.1 Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights • Three presentations at ADA 2025 highlighted the therapeutic potential of icovamenib across multiple aspects of metabolic health: • In patients with type 2 diabetes (T2D) not achieving glycemic targets, icovamenib demonstrated durable HbA1c reduction and improved beta-cell function subsequent to the

As filed with the Securities and Exchange Commission on August 5, 2025

As filed with the Securities and Exchange Commission on August 5, 2025 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40335 Biomea Fusion, Inc.

Form of indenture for senior debt securities and the related form of senior debt security

Exhibit 4.4 BIOMEA FUSION, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [ ] Senior Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities. 4 Section 2.02 Form of Securities and Trustee’s Certificate 6 Sec

Biomea Fusion Appoints Julianne Averill to its Board of Directors

Exhibit 99.1 Biomea Fusion Appoints Julianne Averill to its Board of Directors SAN CARLOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced the appointment of Julianne Averill to its Board of Directors (the “Board”), effective July 22, 2025. Ms. Averill

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2025 Biomea Fusion, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2025 Biomea Fusion, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commission File

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 Biomea Fusion, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commission File

Form of Pre-Funded Warrant

Exhibit 4.1 Form of Pre-Funded Warrant BIOMEA FUSION, INC. WARRANT TO PURCHASE COMMON STOCK Number of Shares: [] (subject to adjustment) Warrant No. [] Original Issue Date: June [], 2025 Biomea Fusion, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [] or its registered assigns (

Amended and Restated Underwriting Agreement, dated as of June 17, 2025, by and between the Company and Jefferies LLC, as representative of the several underwriters named therein.

Exhibit 1.1 Biomea Fusion, Inc. 19,450,000 Shares of Common Stock Pre-Funded Warrants to Purchase 550,000 Shares of Common Stock Warrants to Purchase 20,000,000 Shares of Common Stock (or Pre-Funded Warrants in lieu thereof) Underwriting Agreement June 17, 2025 Jefferies LLC As Representative of the several Underwriters listed in Schedule 1 hereto c/o Jefferies LLC 520 Madison Avenue New York, NY

Form of Common Stock Warrant

EX-4.2 Exhibit 4.2 BIOMEA FUSION, INC. WARRANT TO PURCHASE COMMON STOCK OR PRE-FUNDED WARRANTS Number of Shares: [] (subject to adjustment) Warrant No. [] Original Issue Date: June [ ], 2025 Biomea Fusion, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [] or its registered assig

Form of Pre-Funded Warrant.

EX-4.1 Exhibit 4.1 Form of Pre-Funded Warrant BIOMEA FUSION, INC. WARRANT TO PURCHASE COMMON STOCK Number of Shares: [] (subject to adjustment) Warrant No. [] Original Issue Date: June [], 2025 Biomea Fusion, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [] or its registered as

Biomea Fusion Announces Pricing of Public Offering of Securities

Exhibit 99.2 Biomea Fusion Announces Pricing of Public Offering of Securities REDWOOD CITY, Calif., June 17, 2025 – Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced the pricing of its previously announced underwritten public offering consisting of (i) 19,450,000 shares of its common stock and accompanying warrants to purchase an aggregat

19,450,000 Shares of Common Stock Pre-funded Warrants to Purchase up to 550,000 Shares of Common Stock Warrants to Purchase up to 20,000,000 Shares of Common Stock (or Pre-Funded Warrants)

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-267884 Prospectus supplement (To prospectus dated October 24, 2022) 19,450,000 Shares of Common Stock Pre-funded Warrants to Purchase up to 550,000 Shares of Common Stock Warrants to Purchase up to 20,000,000 Shares of Common Stock (or Pre-Funded Warrants) We are offering 19,450,000 shares of our common stock, $0.0001 par valu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 Biomea Fusion, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 Biomea Fusion, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commission File

Biomea Fusion Announces Proposed Public Offering of Securities

EX-99.1 Exhibit 99.1 Biomea Fusion Announces Proposed Public Offering of Securities REDWOOD CITY, Calif.,– June 17, 2025 – Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, announced today that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded war

Form of Common Stock Warrant.

EX-4.2 Exhibit 4.2 BIOMEA FUSION, INC. WARRANT TO PURCHASE COMMON STOCK OR PRE-FUNDED WARRANTS Number of Shares: [] (subject to adjustment) Warrant No. [] Original Issue Date: June [], 2025 Biomea Fusion, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [] or its registered assign

Underwriting Agreement, dated as of June 17, 2025, by and between the Company and Jefferies LLC, as representative of the several underwriters named therein.

Exhibit 1.1 Biomea Fusion, Inc. 19,450,000 Shares of Common Stock Pre-Funded Warrants to Purchase 550,000 Shares of Common Stock Warrants to Purchase 20,000,000 Shares of Common Stock (or Pre-Funded Warrants in lieu thereof) Underwriting Agreement June 17, 2025 Jefferies LLC As Representative of the several Underwriters listed in Schedule 1 hereto c/o Jefferies LLC 520 Madison Avenue New York, NY

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 Biomea Fusion, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 Biomea Fusion, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commission File

Legal Disclaimer & Forward-Looking Statement Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future business and financial performance of Bio

EX-99.1 Exhibit 99.1 Corporate Update June 2025 Slide 1 Legal Disclaimer & Forward-Looking Statement Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future business and financial performance of Biomea Fusion, Inc. (the “Company”) and involve known and unknown risks, uncertainties and other

Subject to completion, dated June 17, 2025

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-267884 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 Biomea Fusion, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commission File

Employment Offer Letter Agreement by and between the Company and Michael J.M. Hitchcock

Exhibit 10.1 April 2, 2025 Michael J.M. Hitchcock, Ph.D. Dear Michael: I am pleased to offer you employment with Biomea Fusion Inc. (the "Company"). The purpose of this letter is to set forth the terms of your proposed employment with the Company. If you indicate your agreement to the terms in this letter by signing the last page, this letter will constitute your employment agreement with the Comp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40335 Biomea Fusion, Inc.

Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway • Icovamenib progressing toward the next phase of clinical development in ins

Exhibit 99.1 Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway • Icovamenib progressing toward the next phase of clinical development in insulin deficient type 2 diabetes patients and patients that are currently uncontrolled on a GLP-1 based therapy • Biomea's next generation

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits. (d) Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 05, 2025 Biomea Fusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40335 82-2520134 (State or other jurisdiction of incorporation) (Commission File N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential , for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Stat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights • Mick Hitchcock, Ph.D., appointed Interim Chief Executive Officer • Biomea preparing icovamenib for late-stage clinical development • Multiple milesto

Exhibit 99.1 Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights • Mick Hitchcock, Ph.D., appointed Interim Chief Executive Officer • Biomea preparing icovamenib for late-stage clinical development • Multiple milestones anticipated in 2025 including: • FDA meeting anticipated in first half 2025 to discuss icovamenib late-stage development in severe in

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 Biomea Fusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40335 82-2520134 (State or other jurisdiction of incorporation) (Commission File

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of Biomea Fusion, Inc. None.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40335 Biomea Fusion,

Insider Trading Policy

Exhibit 19.1 BIOMEA FUSION, INC. Insider Trading POLICY This memorandum sets forth the policy of Biomea Fusion, Inc. and its subsidiaries, if any (collectively, the “Company”), regarding trading in the Company’s securities as described below and the disclosure of information concerning the Company. This Insider Trading Policy (the “Insider Trading Policy”) is designed to prevent the misuse of mate

Biomea Fusion, Inc.’s Compensation Recovery Policy

Exhibit 97.1 Biomea fusion, inc. COMPENSATION RECOVERY POLICY Adopted as of November 17, 2023 Biomea Fusion, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons (as def

Regulation FD Disclosure, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2025 Biomea Fusion, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commission File

Biomea Fusion Announces Leadership Transition Board member Mick Hitchcock named interim CEO replacing Thomas Butler. COO and President Ramses Erdtmann continuing at Biomea in current role.

Exhibit 99.1 Biomea Fusion Announces Leadership Transition Board member Mick Hitchcock named interim CEO replacing Thomas Butler. COO and President Ramses Erdtmann continuing at Biomea in current role. REDWOOD CITY, California, March 25, 2025 — Biomea Fusion, Inc. (“Biomea,” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, announced today an executive lead

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 Biomea Fusion,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 Biomea Fusion, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commission F

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Biomea Fusion, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commission Fi

Corporate Presentation 43rd Annual J.P. Morgan Healthcare Conference—January 15, 2025

Exhibit 99.2 Corporate Presentation 43rd Annual J.P. Morgan Healthcare Conference—January 15, 2025 Legal Disclaimer & Forward-Looking Statements Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future business and financial performance of Biomea Fusion, Inc. (the “Company”) and involve known

Icovamenib & BMF-650 (oral small molecule GLP-1) are the cornerstones of the metabolic franchise Biomea preparing icovamenib for late-stage clinical development 2025 corporate update to be presented at the 43rd Annual J.P. Morgan Healthcare Conferenc

Exhibit 99.1 Biomea Fusion to Become a Diabetes & Obesity Medicines Company January 13, 2025 Icovamenib & BMF-650 (oral small molecule GLP-1) are the cornerstones of the metabolic franchise Biomea preparing icovamenib for late-stage clinical development 2025 corporate update to be presented at the 43rd Annual J.P. Morgan Healthcare Conference REDWOOD CITY, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) —

Filing Fee Table

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Biomea Fusion, Inc.

As filed with the U.S. Securities and Exchange Commission on January 6, 2025

S-8 As filed with the U.S. Securities and Exchange Commission on January 6, 2025 Registration No. 333-    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOMEA FUSION, INC. (Exact name of registrant as specified in its charter) Delaware 82-2520134 (State or other jurisdiction of incorporation or organization)

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2024 Biomea Fusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40335 82-2520134 (State or other jurisdiction of incorporation) (Commission F

COVALENT-111 Topline Results - Conference Call December 17, 2024 Agenda Thomas Butler Introduction & Chief Executive Officer, Chairman of the Board & Co-Founder of Biomea Fusion Executive Summary COVALENT-111 Dr. Juan Pablo Frias Chief Medical Office

Exhibit 99.2 COVALENT-111 Topline Results December 17, 2024 COVALENT-111 Topline Results - Conference Call December 17, 2024 Agenda Thomas Butler Introduction & Chief Executive Officer, Chairman of the Board & Co-Founder of Biomea Fusion Executive Summary COVALENT-111 Dr. Juan Pablo Frias Chief Medical Officer of Biomea Fusion Topline Results Dr. Alex Abitbol Key Opinion LMC Healthcare, Endocrinol

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

Exhibit 99.1 Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes December 17, 2024 • Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient population • Best response achieved in target, beta-cell deficient patient

BMEA / Biomea Fusion, Inc. / Laurion Capital Management LP - LAURION CAPITAL MANAGEMENT LP Passive Investment

SC 13G/A 1 bmeaa1111224.htm LAURION CAPITAL MANAGEMENT LP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Biomea Fusion Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 09077A106 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of thi

Legal Disclaimer & Forward-Looking Statements Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future business and financial performance of Bi

BIOMEA cONFERENCE Call Preclinical Data Combining icovamenib with a GLP-1-Based Therapy & Biomea’s Oral GLP-1 RA Candidate BMF-650 October 30, 2024 Exhibit 99.

Biomea Fusion Presents Preclinical Data Showing Icovamenib

Exhibit 99.2 Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate • Preclinical data from ex vivo human islet experiments showed that icovamenib (BMF-219) was able to enhance the activity of glucagon-like peptide-1 (GLP-1)-based therapies,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 Biomea Fusion, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 Biomea Fusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40335 82-2520134 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40335 Biomea Fusion, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2024 Biomea Fusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40335 82-2520134 (State or other jurisdiction of incorporation) (Commission Fi

- See attached for financial tables - BIOMEA FUSION, INC. Condensed Statement of Operations and Comprehensive Loss (in thousands, except share and per share data)

Exhibit 99.1 Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights • U.S. Food and Drug Administration (FDA) lifted Clinical Hold on COVALENT-111 (Type 2 Diabetes) & COVALENT-112 (Type 1 Diabetes) trials • COVALENT-111 Phase 2b 26-week topline data of the dose expansion cohorts expected in December 2024 • COVALENT-112 Phase 2a 26-week topline data of the open label po

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2024 Biomea Fusion,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2024 Biomea Fusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40335 82-2520134 (State or other jurisdiction of incorporation) (Commission

FDA Lifts Clinical Hold on

EX-99.1 Exhibit 99.1 FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials REDWOOD CITY, Calif., September 26, 2024 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and

- See attached for financial tables - BIOMEA FUSION, INC. Condensed Statement of Operations and Comprehensive Loss (in thousands, except share and per share data)

Exhibit 99.1 Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights • COVALENT-111 Phase 2b on track for Q4 2024 readout • COVALENT-112 Phase 2a on track for Q4 2024 readout • Announcement of the third program in obesity on track for Q3 2024 REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) - Biomea Fusion, Inc. (“Biomea” or “the Company”) (Nasdaq: BMEA), a clinica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40335 Biomea Fusion, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2024 Biomea Fusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40335 82-2520134 (State or other jurisdiction of incorporation) (Commission File

June 21, 2024

June 21, 2024 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2024 Biomea Fusion, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2024 Biomea Fusion, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commission File

Biomea Fusion Announces

EX-99.1 Exhibit 99.1 Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold REDWOOD CITY, Calif., June 6, 2024 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), announced that the Company has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea’s ongoing Phase I/II clinical trials of the C

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 Biomea Fusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40335 82-2520134 (State or other jurisdiction of incorporation) (Commission File N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 02, 2024 Biomea Fusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40335 82-2520134 (State or other jurisdiction of incorporation) (Commission File N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40335 Biomea Fusion, Inc.

Offer Letter, dated July 24, 2023, by and between the Registrant and Juan Pablo Frias

Exhibit 10.1 July 24, 2023 Juan Pablo Frias, MD Dear Juan, I am pleased to offer you employment with Biomea Fusion Inc. (the "Company"). The purpose of this letter is to set forth the terms of your proposed employment with the Company. If you indicate your agreement to the terms in this letter by signing the last page, this letter will constitute your employment agreement with the Company (the "Ag

- See attached for financial tables - BIOMEA FUSION, INC. Condensed Statement of Operations and Comprehensive Loss (in thousands, except share and per share data)

Exhibit 99.1 Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights • Reported positive data from the escalation portion of Phase 1/2 study (COVALENT-111) in type 2 diabetes patients, displaying durable improved glycemic control while off therapy for 22 weeks, supporting the disease-modifying potential of BMF-219 to address a root cause of diabetes: a loss of healthy,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 01, 2024 Biomea Fusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40335 82-2520134 (State or other jurisdiction of incorporation) (Commission File

Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with

Exhibit 99.1 Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219 BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes • The first two type 1 diabetes patients enrolled in COVALENT-112 both demonstrated early signs of clinical activity with improved measures of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 Biomea Fusion, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 Biomea Fusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40335 82-2520134 (State or other jurisdiction of incorporation) (Commission File

- See attached for financial tables - BIOMEA FUSION, INC. Condensed Statement of Operations and Comprehensive Loss (in thousands, except share and per share data)

Exhibit 99.1 Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights • In 2023, reported Phase 2 data (COVALENT-111) in type 2 diabetes patients supporting the disease-modifying potential of BMF-219 to address a root cause of diabetes: a loss of healthy, insulin-producing beta cells. o After just a 4-week treatment period in type 2 diabetes patients, who

Biomea Fusion, Inc.’s Compensation Recovery Policy

Exhibit 97.1 Biomea fusion, inc. COMPENSATION RECOVERY POLICY Adopted as of November 17, 2023 Biomea Fusion, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons (as def

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of Biomea Fusion, Inc. None. ACTIVE/115593365.1

Updated Form Executive Change in Control and Severance Agreement adopted November 13, 2023

Exhibit 10-5(c) UPDATED FORM EXECUTIVE CHANGE IN CONTROL AND SEVERANCE AGREEMENT ADOPTED NOVEMBER 13, 2023 This Change in Control and Severance Agreement (the “Agreement”) is made and entered into by and between NAME (“Executive”) and Biomea Fusion, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40335 Biomea Fusion,

Poster presentation titled, “Durable Glycemic Control With BMF-219 During Off-Treatment Period at Week 26: a Phase 1/2 Trial of BMF-219 in Patients with Type 2 Diabetes (Covalent-111).”

EX-99.2 DURABLE GLYCEMIC CONTROL WITH BMF-219 DURING OFF-TREATMENT PERIOD AT WEEK 26: Exhibit 99.2 A PHASE 1/2 TRIAL OF BMF-219 IN PATIENTS WITH TYPE 2 DIABETES (COVALENT-111) 1 2 3 4 5 6 7 7 7 7 7 7 Jose Rodriguez , Alexander Abitbol , Douglas Denham , Rizwana Mohseni , Janice Faulknor , Cesar Perez , Brian Munneke , Courtney Follit , Juan Frias , Sanchita Mourya , Thomas Butler , Steve Morris ;

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2024 Biomea Fusion, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2024 Biomea Fusion, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commission File

Poster presentation titled, “Key Observations from the Dose-Escalation Portion of Covalent-111, a Phase 1/2 Trial of the Covalent Menin Inhibitor BMF-219 in Patients with Type 2 Diabetes.”

KEY OBSERVATIONS FROM THE DOSE-ESCALATION PORTION OF COVALENT-111, A PHASE 1/2 Exhibit 99.

Biomea Fusion Presents Patient Cohorts in

Exhibit 99.1 Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function Three Clinical Data Sets from the Dose Escalation Phase of COVALENT-111 to be Presented at the 17th Annual ATTD Conference Highlighting BMF-219’s

Poster presentation titled, “Case Studies from Covalent-111, a Phase 1/2 Trial Of BMF-219, a Covalent Menin Inhibitor, in Patients with Type 2 Diabetes.”

CASE STUDIES FROM COVALENT-111, A PHASE 1/2 TRIAL OF BMF-219, A COVALENT MENIN Exhibit 99.

BMEA / Biomea Fusion, Inc. / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment

SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No.

BMEA / Biomea Fusion, Inc. / Erdtmann Rainer M - SC 13G/A Passive Investment

SC 13G/A 1 d725490dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Biomea Fusion, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09077A106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design

BMEA / Biomea Fusion, Inc. / Butler Thomas Andrew - SC 13G/A Passive Investment

SC 13G/A 1 d665198dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Biomea Fusion, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09077A106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design

BMEA / Biomea Fusion, Inc. / Laurion Capital Management LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Disclaimer Legal Disclaimer & Forward-Looking Statements Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future business and financial perfor

Exhibit 99.1 JP Morgan 2024 Corporate Presentation Page 1 Disclaimer Legal Disclaimer & Forward-Looking Statements Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future business and financial performance of Biomea Fusion, Inc. (the “Company”) and involve known and unknown risks, uncertaint

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2024 Biomea Fusion, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commission Fil

Form of Restricted Stock Award Agreement under the 2023 Inducement Plan

EX-99.3(c) Exhibit 99.3(c) BIOMEA FUSION, INC. 2023 INDUCEMENT PLAN RESTRICTED STOCK AWARD GRANT NOTICE Biomea Fusion, Inc., a Delaware corporation, (the “Company”), pursuant to its 2023 Inducement Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”) the number of shares of the Company’s Common Stock set forth below (the “Shares”) as an induceme

2023 Inducement Plan

EX-99.3(a) Exhibit 99.3(a) BIOMEA FUSION, INC. 2023 INDUCEMENT PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enable the Company to grant equity awards to induce highly-qualified prospective officers and employees who are not currently employed by the Company or any of its Subsidiaries to accept employment and provide these individuals with a proprietary interest in the Company. The Company inte

Form of Restricted Stock Unit Agreement under the 2023 Inducement Plan

EX-99.3(d) Exhibit 99.3(d) BIOMEA FUSION, INC. 2023 INDUCEMENT PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Biomea Fusion, Inc., a Delaware corporation, (the “Company”), pursuant to its 2023 Inducement Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”), an award of restricted stock units (“Restricted Stock Units” or “RSUs”) as an inducement p

As filed with the U.S. Securities and Exchange Commission on January 5, 2024

S-8 As filed with the U.S. Securities and Exchange Commission on January 5, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOMEA FUSION, INC. (Exact name of registrant as specified in its charter) Delaware 82-2520134 (State or other jurisdiction of incorporation or organization) (I

Form of Non-Qualified Stock Option Agreement under the 2023 Inducement Plan

EX-99.3(b) Exhibit 99.3(b) BIOMEA FUSION, INC. 2023 INDUCEMENT PLAN NONQUALIFIED STOCK OPTION GRANT NOTICE Biomea Fusion, Inc., a Delaware corporation, (the “Company”), pursuant to its 2023 Inducement Plan, as may be amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”), an option to purchase the number of shares of the Company’s Common Stock (the “Shares

Filing Fee Table

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Biomea Fusion, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40335 Biomea Fusion, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2023 Biomea Fusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40335 82-2520134 (State or other jurisdiction of incorporation) (Commission Fi

- See attached for financial tables - BIOMEA FUSION, INC. Condensed Statement of Operations (in thousands, except share and per share amounts)

Exhibit 99.1 Biomea Fusion Reports Third Quarter 2023 Financial Results and Corporate Highlights • Demonstrated durable HbA1c lowering in the escalation portion of ongoing Phase II study in type 2 diabetes (COVALENT-111), with 84% of all patients showing a reduction of HbA1c after 4 weeks dosing and 74% after another 8 weeks off-treatment period • Expansion portion of COVALENT-111 cleared and acti

- See attached for financial tables - BIOMEA FUSION, INC. Condensed Statement of Operations (in thousands, except share and per share amounts)

Exhibit 99.1 Biomea Fusion Reports Second Quarter 2023 Financial Results and Corporate Highlights • Reported additional positive clinical data at ADA 83rd Scientific Sessions from the first two cohorts of patients with type 2 diabetes from ongoing Phase I/II study (COVALENT-111) evaluating BMF-219 as a novel, potentially disease-modifying treatment candidate for patients with type 2 diabetes o New

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 Biomea Fusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40335 82-2520134 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40335 Biomea Fusion, Inc.

BMF-219 Induces Complete Responses in Target Acute Myeloid Leukemia (AML) Patient Population

EX-99.1 Exhibit 99.1 BMF-219 Induces Complete Responses in Target Acute Myeloid Leukemia (AML) Patient Population • Initial topline data from COVALENT-101 trial revealed 2 complete responses (CRs) out of 5 relapsed/refractory AML patients carrying menin-dependent mutations treated at Dose Level 4 • Dose Level 4 exposure correlates with initial activity seen in BMF-219’s pre-clinical studies • Safe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 Biomea Fusion, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 Biomea Fusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40335 82-2520134 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 Biomea Fusion, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 Biomea Fusion, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 02, 2023 Biomea Fusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40335 82-2520134 (State or other jurisdiction of incorporation) (Commission File N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40335 Biomea Fusion, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 Biomea Fusion, Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 Biomea Fusion, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commission File Nu

- See attached for financial tables - BIOMEA FUSION, INC. Condensed Statement of Operations (in thousands, except share and per share amounts)

Exhibit 99.1 Biomea Fusion Reports First Quarter 2023 Financial Results and Corporate Highlights • Reported initial positive clinical data from first two cohorts of Phase II of ongoing Phase I/II study (COVALENT-111) of BMF-219, Biomea’s lead investigational, orally administered covalent menin inhibitor, as a novel, potentially disease-modifying treatment for patients with type 2 diabetes • Contin

Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent FLT3 Inhibitor

EX-99.1 Exhibit 99.1 Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia • BMF-500, a novel 3rd generation covalent inhibitor of fms-like tyrosine kinase 3 (FLT3), is the second investigational compound, discovered and developed by Biomea’s FUSION™ System, to advance to the clinic. • Phase

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Underwriting Agreement, dated as of March 29, 2023, by and between the Company and J.P. Morgan Securities LLC and Citigroup Global Markets Inc., as representatives of the several underwriters named therein.

Exhibit 1.1 Biomea Fusion, Inc. 5,000,000 Shares of Common Stock, par value $0.0001 per share Underwriting Agreement March 29, 2023 J.P. Morgan Securities LLC Citigroup Global Markets Inc. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, NY

Page 1 of 3

EX-99.1 Exhibit 99.1 Biomea Fusion Announces Proposed Public Offering of Common Stock REDWOOD CITY, Calif.,– March 29, 2023 – Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, announced tod

BMEA / Biomea Fusion Inc / Cormorant Global Healthcare Master Fund, LP - AMENDMENT NO. 1 Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Biomea Fusion, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09077A106 (CUSIP Number) Neb Obradovic Cormorant Asset Management, L.P. 200 Clarendon Street, 52nd Floor Boston, MA 02116 Tel. No.: 857-702-0386 (Name, Address and Telephone

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2023 Biomea Fusion, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2023 Biomea Fusion, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commission File

Biomea Fusion Announces Pricing of Upsized Public Offering of Common Stock

EX-99.2 Exhibit 99.2 Biomea Fusion Announces Pricing of Upsized Public Offering of Common Stock REDWOOD CITY, Calif., March 29, 2023 – Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, toda

Biomea Fusion, Inc. 900 Middlefield Road, 4th Floor Redwood City, CA 94063 Attention: Secretary (650) 980-9099

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-267884 Prospectus supplement (To prospectus dated October 24, 2022) 5,000,000 shares Common stock We are offering 5,000,000 shares of our common stock. Our common stock is listed on The Nasdaq Global Select Market under the symbol “BMEA.” On March 29, 2023, the last reported sale price of our common stock on The Nasdaq G

Biomea Fusion, Inc. 900 Middlefield Road, 4th Floor Redwood City, CA 94063 Attention: Secretary (650) 980-9099

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-267884 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to

COVALENT-111 First Data Readout of Initial Cohorts - Conference Call March 28, 2023 Legal Disclaimer & Forward-Looking Statements Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These state

EX-99.2 Exhibit 99.2 COVALENT-111: Phase II First Data Readout of Initial Healthy Volunteer (HV) and Type 2 Diabetes Mellitus (T2DM) Cohorts March 28, 2023 COVALENT-111 First Data Readout of Initial Cohorts - Conference Call March 28, 2023 Legal Disclaimer & Forward-Looking Statements Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of Biomea Fusion, Inc. None. ACTIVE/115593365.1

- See attached for financial tables - BIOMEA FUSION, INC. Condensed Statement of Operations (in thousands, except share and per share amounts)

Exhibit 99.1 Biomea Fusion Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights • Expanded clinical development footprint of BMF-219, the company’s lead investigational, orally administered, covalent menin inhibitor, to eight liquid and solid tumor indications and type 2 diabetes across three ongoing clinical trials o COVALENT-101 (Phase I study) enrolling four liqu

Form 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2023 Biomea Fusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40335 82-2520134 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2023 Biomea Fusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40335 82-2520134 (State or other jurisdiction of incorporation) (Commission File

Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40335 Biomea Fusion,

Biomea Fusion Announces Positive Data from Initial Cohorts of Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes; 100 mg Cohort 3 Demonstrated an 89% Response Rate and 1% Median Reduction in HbA1c at Day 28

EX-99.1 Exhibit 99.1 Biomea Fusion Announces Positive Data from Initial Cohorts of Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes; 100 mg Cohort 3 Demonstrated an 89% Response Rate and 1% Median Reduction in HbA1c at Day 28 • In Cohort 3, after 4 weeks of once-daily 100 mg dosing with the investigational, oral covalent menin inhibitor, BMF-219, 89% of patients ac

AGREEMENT

EX-99.1 2 tm234999d10ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Biomea Fusion, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them. February 14, 2023 BAKER BROS. ADVISORS

BMEA / Biomea Fusion, Inc. / BAKER BROS. ADVISORS LP - SC 13G Passive Investment

SC 13G 1 tm234999d10sc13g.htm SC 13G SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. )* Biomea Fusion, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 09077A106 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box

BMEA / Biomea Fusion, Inc. / Erdtmann Rainer M - SC 13G/A Passive Investment

SC 13G/A 1 d438702dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Biomea Fusion, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09077A106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design

BMEA / Biomea Fusion, Inc. / Butler Thomas Andrew - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Biomea Fusion, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09077A106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

Disclaimer Legal Disclaimer & Forward-Looking Statements Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future business and financial perfor

Exhibit 99.2 JP Morgan 2023 Corporate Presentation 1 Disclaimer Legal Disclaimer & Forward-Looking Statements Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future business and financial performance of Biomea Fusion, Inc. (the “Company”) and involve known and unknown risks, uncertainties a

Biomea Fusion to Present at 41

Exhibit 99.1 Biomea Fusion to Present at 41st Annual J.P. Morgan Healthcare Conference and Highlight 2023 Corporate Milestones REDWOOD CITY, Calif., Jan. 9, 2023 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined c

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 Biomea Fusion, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commission Fil

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Biomea Fusion, Inc.

As filed with the U.S. Securities and Exchange Commission on January 4, 2023

As filed with the U.S. Securities and Exchange Commission on January 4, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOMEA FUSION, INC. (Exact name of registrant as specified in its charter) Delaware 82-2520134 (State or other jurisdiction of incorporation or organization) (I.R.S

Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent Menin Inhibitor

Exhibit 99.1 Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent Menin Inhibitor BMF-219 in Type 2 Diabetes ? COVALENT-111, a Phase I/II clinical trial in patients with type 2 diabetes, already underway in Canada, will now activate sites in the US ? As previously reported, the Phase I portion of COVALENT-111 has been completed, with BMF-219 demonstratin

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2022 Biomea Fusion, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commission F

Biomea Fusion Presents at the 2022 ASH Annual Meeting Preclinical Data on

Exhibit 99.1 Biomea Fusion Presents at the 2022 ASH Annual Meeting Preclinical Data on BMF-500 Supporting its Potential as the Most Potent and Selective FLT3 Inhibitor to Date ? BMF-500, an investigational third generation covalent FLT3 inhibitor, demonstrated preclinically: ? Picomolar affinity to activating FLT3 mutations including FLT3-ITD and various tyrosine kinase domain (TKD) mutations ? Mu

Presentation titled, “BMF-500: An Orally Bioavailable Covalent Inhibitor of FLT3 with High Selectivity and Potent Antileukemic Activity in FLT3-Mutated AML.”

EX-99.2 3 d424536dex992.htm EX-99.2 Exhibit 99.2 Abstract 2756 ASH Dec. 10 – 13, 2022 BMF-500: An Orally Bioavailable Covalent Inhibitor of FLT3 with High Selectivity and Potent Antileukemic Activity in FLT3-Mutated AML Brian Law, BS1, Tripta Rughwani, MS1, Tenley Archer PhD1, Lekha Kumar, MS1, Daniel Lu, MS1, Priyanka Somanath, PhD1, Yan Ma, PhD1, Xiaodong Wang, MS*1, David Sperandio, PhD1, Steve

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2022 Biomea Fusion, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commission F

Equity Distribution Agreement, dated November 25, 2022, by and between the Company and Piper Sandler & Co.

EX-1.1 2 d721850dex11.htm EX-1.1 Exhibit 1.1 BIOMEA FUSION, INC. EQUITY DISTRIBUTION AGREEMENT November 25, 2022 PIPER SANDLER & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: As further set forth in this agreement (this “Agreement”), Biomea Fusion, Inc., a company organized under the laws of Delaware (the “Company”), proposes to issue and sell from ti

Piper Sandler The date of this prospectus supplement is November 25, 2022

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-267884 PROSPECTUS SUPPLEMENT (To prospectus dated October 24, 2022) Up to $100,000,000 Common Stock We have entered into an equity distribution agreement, or the equity distribution agreement, with Piper Sandler & Co., or Piper Sandler, dated November 25, 2022, relating to shares of our common stock offered by this prospectus

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2022 Biomea Fusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40335 82-2520134 (State or other jurisdiction of incorporation) (Commission F

- See attached for financial tables - BIOMEA FUSION, INC. Condensed Statement of Operations (in thousands, except share and per share amounts)

Exhibit 99.1 Biomea Fusion Reports Third Quarter 2022 Financial Results and Business Highlights ? Continued to establish Biomea Fusion as the next-generation leader in covalent medicines ? Expanded clinical development footprint of BMF-219, the company?s lead investigational, orally administered, covalent menin inhibitor, in multiple liquid and solid tumor indications, including first in class pot

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2022 Biomea Fusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40335 82-2520134 (State or other jurisdiction of incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40335 Biomea Fusion, Inc.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2022 Biomea Fusion, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commission Fi

Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes and Completion of Phase I Healthy Volunteer Portion of Phase I/II

Exhibit 99.1 Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes and Completion of Phase I Healthy Volunteer Portion of Phase I/II (COVALENT-111) Study of BMF-219 ? BMF-219 is the first menin inhibitor to reach the clinic for type 2 diabetes. The Phase II portion of COVALENT-111 is designed to examine the capacity of BMF-219 to provide long-term glycemic control by restoring the p

Biomea Fusion, Inc. 900 Middlefield Road, 4th Floor Redwood City, CA 94063

Biomea Fusion, Inc. 900 Middlefield Road, 4th Floor Redwood City, CA 94063 October 20, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance ? Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Biomea Fusion, Inc. Registration Statement on Form S-3 File No. 333-267884 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 under the Securi

BMF-219 Enters the Clinic for KRAS Solid Tumors

Exhibit 99.1 BMF-219 Enters the Clinic for KRAS Solid Tumors ? Biomea Fusion announces FDA clearance of Investigational New Drug (IND) application for covalent menin inhibitor BMF-219 in KRAS solid tumors. ? Biomea Fusion will now initiate a Phase I/Ib clinical trial (COVALENT-102) of BMF-219 as a monotherapy in patients who have unresectable, locally advanced, or metastatic non-small cell lung ca

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2022 Biomea Fusion, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commission Fi

Filing Fee Table.

Exhibit 107 Calculation of Filing Fees Table Form S-3 (Form Type) Biomea Fusion, Inc.

As filed with the Securities and Exchange Commission on October 14, 2022

Table of Contents As filed with the Securities and Exchange Commission on October 14, 2022 Registration No.

Form of indenture for subordinated debt securities and the related form of subordinated debt security.

Exhibit 4.5 BIOMEA FUSION, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities. 4 Section 2.02 Form of Securities and Trustee?s Certificate

Form of indenture for senior debt securities and the related form of senior debt security.

Exhibit 4.4 BIOMEA FUSION, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [ ] Senior Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities. 4 Section 2.02 Form of Securities and Trustee?s Certificate 6 Sec

Biomea Fusion Presents New Translational Data at the European Association for the Study of Diabetes (EASD) 2022 in Animal Models and Ex-vivo Human Donor Islets Further Supporting BMF-219’s Potential as an Oral, Long-Acting Treatment for Type 2 Diabet

Exhibit 99.1 Biomea Fusion Presents New Translational Data at the European Association for the Study of Diabetes (EASD) 2022 in Animal Models and Ex-vivo Human Donor Islets Further Supporting BMF-219?s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes September 22, 2022, at 9:30 AM EDT ???Treatment with BMF-219 led to an increase in beta cell mass in ex-vivo experiments with human do

Our understanding of diabetes has evolved; Progression of type 1 and type 2 diabetes are both driven by beta cell loss Progression of Type 2 Diabetes “Understanding of Diabetes has evolved” Pipeline-in-a-Pill – Single Agent for Multiple Indications M

Exhibit 99.2 Presentation # 197 Oral long-acting menin inhibitor normalizes type 2 diabetes in two rat models *Thomas Butler, Sanchita Mourya, Weiqun Li, Tenley Archer, Taisei Kinoshita, Mini Balakrishnan, Priyanka Somanath EASD Annual Meeting 2022 Oral Presentation Golgi Hall Session: OP 33 Therapy outside the box 1 September 22, 2022 Our understanding of diabetes has evolved; Progression of type

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2022 Biomea Fusion, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commission

Menin: A novel target for beta-cell homeostasis Potential Mechanism of Menin in Diabetes BMF-219: A selective covalent menin inhibitor ▪ Menin is an epigenetic protein that plays a key role in regulating NPM1 beta-cell proliferation and function. BMF

Exhibit 99.2 Presentation #590 Oral Menin Inhibitor, BMF-219, displays a significant and durable reduction in HbA1c in a Type 2 Diabetes Rat Model Priyanka Somanath, Sanchita Mourya, Weiqun Li, Tenley Archer, Brian Law, Daniel Lu, Tripta Rughwani, Lekha Kumar, Taisei Kinoshita, Mini Balakrishnan, Thomas Butler EASD Annual Meeting 2022 September 20, 2022 1 Menin: A novel target for beta-cell homeos

Biomea Fusion Presents New Preclinical Data at the European Association for the Study of Diabetes (EASD) Annual Meeting Describing

Exhibit 99.1 Biomea Fusion Presents New Preclinical Data at the European Association for the Study of Diabetes (EASD) Annual Meeting Describing BMF-219?s Potential as a Novel, Oral, Long-Acting Treatment for Type 2 Diabetes September 20, 2022, at 2:45 AM PDT ? Menin, a transcriptional scaffold protein, regulates pancreatic beta cell homeostasis; inhibiting menin function with BMF-219 increased bet

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2022 Biomea Fusion, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commission

Sublease Agreement between the Registrant and Box, Inc., dated September 7, 2022

Exhibit 10.1 Execution Version SUBLEASE This Sublease (?Sublease?), dated September 7, 2022 (the ?Execution Date?), is entered into by and between BOX, INC., a Delaware corporation (?Sublandlord?), and BIOMEA FUSION, INC., a Delaware corporation (?Subtenant?). 1. BASIC SUBLEASE PROVISIONS 1.1 Premises: The premises under this Sublease are deemed by the parties to consist of 27,003 rentable square

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2022 Biomea Fusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40335 82-2520134 (State or other jurisdiction of incorporation) (Commission F

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2022 Biomea Fusion, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commission Fil

Biomea Fusion Presents Additional Preclinical Data Demonstrating Anti- Tumor Activity and Mechanistic Evidence for

Exhibit 99.1 Biomea Fusion Presents Additional Preclinical Data Demonstrating Anti- Tumor Activity and Mechanistic Evidence for BMF-219 in Diffuse Large B-Cell Lymphoma and Multiple Myeloma Models at International Myeloma Society Annual Meeting ? Data demonstrated robust anti-tumor activity of BMF-219 and mechanistic evidence for novel inhibition of menin protein in preclinical models of Diffuse L

Poster presentation titled, “COVALENT-101: Phase 1 first-in-human dose escalation and dose-expansion study of BMF-219, an oral, covalent, menin inhibitor, in adult patients with acute leukemia (AL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma (MM).”

Exhibit 99.3 COVALENT-101 (NCT05153330) Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral, covalent, menin inhibitor, in adult patients with acute leukemia (AL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma (MM) 1 3 3 4 5 6 7 7 7 7 2 Farhad Ravandi, MD ; Hetty Carraway, MD ; Jack Khouri, MD ; Ashwin Kishtagari, MD ; Emily Curran, MD ; Gary Schiller,

Poster presentation titled, “Anti-tumor Activity of Covalent Menin Inhibitor, BMF-219, in High Grade B-Cell Lymphoma and Multiple Myeloma Preclinical Models.”

Exhibit 99.2 Anti-tumor Activity of Covalent Menin Inhibitor, BMF-219, in High Grade B-Cell Lymphoma and Multiple Myeloma Preclinical Models 1 1 1 1 1 1 1 1 Daniel Lu, MS Priyanka Somanath, PhD , Brian Law, BS , Lekha Kumar, MS , James T. Palmer, PhD , Taisei Kinoshita, PhD , Mini Balakrishnan, PhD and Thomas Butler, MSc MBA , 1 Biomea Fusion, Inc. Redwood City, CA BMF-219 exerts pronounced lethal

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 01, 2022 Biomea Fusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40335 82-2520134 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40335 Biomea Fusion, Inc.

- See attached for financial tables - BIOMEA FUSION, INC. Condensed Statement of Operations (in thousands, except share and per share amounts)

Exhibit 99.1 Biomea Fusion Reports Second Quarter 2022 Financial Results and Business Highlights ? Continued to make significant progress advancing BMF-219, the company?s lead investigational orally administered covalent menin inhibitor, in multiple oncology indications o COVALENT-101 (Phase I) study is enrolling for patients with Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), D

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2022 BIOMEA FUSION, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commission File

Menin is a scaffold protein, encoded by the gene MEN1, that has been recently . recognized for its role in Type 2 Diabetes Mellitus (T2DM) as a key regulator of

Exhibit 99.2 Menin is a scaffold protein, encoded by the gene MEN1, that has been recently . recognized for its role in Type 2 Diabetes Mellitus (T2DM) as a key regulator of b-cell proliferation. Men1 knockout mice demonstrate increased B-cell mass generation (Yang et al., 2010) Menin inhibition has previously been shown to improve glycemic control in high fat induced diabetic mice (Ma et al., 202

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2022 Biomea Fusion, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commission File N

Preclinical Activity of irreversible menin inhibitor,

Exhibit 99.1 Preclinical Activity of irreversible menin inhibitor, BMF-219, in Chronic Lymphocytic LeukemiaPriyanka Somanath, PhD1, Daniel Lu, MS 1 Brian Law, BS 1, Lekha Kumar, MS1, Tenley Archer, PhD, Tripta Rughwani, MS, Taisei Kinoshita, PhD1, Mini Balakrishnan, PhD1 and Thomas Butler, MSc MBA1,1Biomea Fusion, Inc. Redwood City, CAIntroductionMenin is a scaffold protein that drives oncogenic f

Oral Menin Inhibitor,

Exhibit 99.3 Oral Menin Inhibitor, BMF-219, displays a significant and durable reduction in HbA1c in a Type 2 Diabetes Mellitus Rat ModelPriyanka Somanath, PhD1,, Sanchita Mourya, MD1, Weiqun Li, PhD1, Brian Law, BS 1, Tenley Archer, PhD, Daniel Lu, MS, Tripta Rughwani, Lekha Kumar, Taisei Kinoshita, PhD1, Mini Balakrishnan, PhD1 and Thomas Butler, MSc MBA1 1Biomea Fusion, Inc. Redwood City, CAInt

Form of Indemnification and Advancement Agreement for Directors and Officers

Exhibit 10.1 INDEMNIFICATION And Advancement AGREEMENT This Indemnification and Advancement Agreement (?Agreement?) is made as of [ ? ], 20[ ? ] by and between Biomea Fusion, Inc., a Delaware corporation (the ?Company?), and , [a member of the Board of Directors/an officer/an employee/an agent/a fiduciary] of the Company (?Indemnitee?). This Agreement supersedes and replaces any and all previous A

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 Biomea Fusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40335 82-2520134 (State or other jurisdiction of incorporation) (Commission File N

- See attached for financial tables - BIOMEA FUSION, INC. Condensed Statement of Operations (in thousands, except share and per share amounts)

Exhibit 99.1 Biomea Fusion Reports First Quarter 2022 Financial Results and Business Highlights ? COVALENT-101 study continues to enroll relapsed/refractory (R/R) acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) patients and has included R/R diffuse large B-cell lymphoma (DLBCL) and R/R multiple myeloma (MM) patients to the study. Company continues to explore indication expansion

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40335 Biomea Fusion, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

Definitive Proxy Statement

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2022 Biomea Fusion, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40335 82-2520134 (State or other jurisdiction of incorporation) (Commission File

FIRST AMENDMENT TO CHANGE IN CONTROL AND SEVERANCE AGREEMENT

Exhibit 99.1 FIRST AMENDMENT TO CHANGE IN CONTROL AND SEVERANCE AGREEMENT This First Amendment to Change in Control and Severance Agreement (this ?Amendment?) is executed as of [?], 2022, by and between Biomea Fusion, Inc., a Delaware corporation (the ?Company?), and [?] (the ?Executive?). WHEREAS, the Company and Executive are parties to a certain Biomea Fusion, Inc. Change in Control and Severan

Biomea Fusion Reports Preclinical Data on BMF-219 and Trial in Progress Presentations at AACR 2022 Annual Meeting

Exhibit 99.1 Biomea Fusion Reports Preclinical Data on BMF-219 and Trial in Progress Presentations at AACR 2022 Annual Meeting April 8, 2022 ? Covalent menin inhibitor BMF-219 showed strong cytotoxic activity as a single agent at similar concentrations across multiple preclinical patient derived (PDX) models ex vivo, including diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), colorecta

Poster presentation titled, “A Phase 1 study of BMF-219, a novel oral irreversible menin inhibitor, as a single agent in patients with relapsed/refractory (R/R) acute lymphocytic/acute myeloid leukemia (ALL/AML), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma (MM).”

Exhibit 99.4

Poster presentation titled, “Anti-tumor Activity of Irreversible Menin Inhibitor, BMF-219, in High Grade B-Cell Lymphoma and Multiple Myeloma Preclinical Models.”

Exhibit 99.3

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2022 Biomea Fusion, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commission File

Poster presentation titled, “Irreversible Menin Inhibitor, BMF-219, Exhibits Potent Cytotoxicity in KRAS-Mutated Solid Tumors.”

Exhibit 99.2

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of Biomea Fusion, Inc. None. ACTIVE/115593365.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40335 Biomea Fusion,

Biomea Fusion Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

Exhibit 99.1 Biomea Fusion Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights ? Phase I trial of BMF-219, an irreversible covalent menin inhibitor, is currently underway ? Plan to initiate trials of BMF-219 in up to seven solid and liquid tumor types and diabetes ? Plan to announce second clinical candidate in the first half of 2022 ? Cash, cash equivalents, restr

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Biomea Fusion, Inc. Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 Biomea Fusion, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commiss

BMEA / Biomea Fusion, Inc. / Boxer Capital, LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Biomea Fusion, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 09077A106 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the ru

BMEA / Biomea Fusion, Inc. / Erdtmann Rainer M - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Biomea Fusion, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09077A106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche

BMEA / Biomea Fusion, Inc. / Butler Thomas Andrew - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Biomea Fusion, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09077A106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Biomea Fusion, Inc.

As filed with the U.S. Securities and Exchange Commission on February 2, 2022

As filed with the U.S. Securities and Exchange Commission on February 2, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOMEA FUSION, INC. (Exact name of registrant as specified in its charter) Delaware 82-2520134 (State or other jurisdiction of incorporation or organization) (I.R.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2022 Biomea Fusion, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commission Fi

Disclaimer and Forward-Looking Statement Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future business and financial performance of Biomea

Exhibit 99.1 Corporate Presentation January 2022 1 Disclaimer and Forward-Looking Statement Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future business and financial performance of Biomea Fusion, Inc. (the ?Company?) and involve known and unknown risks, uncertainties and other factors t

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Biomea Fusion, Inc. Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2021 Biomea Fusion, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commiss

Biomea fusion tm Corporate Presentation November 2021

Exhibit 99.1 Biomea fusion tm Corporate Presentation November 2021 Disclaimer and Forward-Looking Statement Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future financial performance of Biomea Fusion, Inc. (the ?Company?) and involve known and unknown risks, uncertainties and other factor

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Biomea Fusion, Inc. Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2021 Biomea Fusion, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commissi

Biomea Fusion Reports Third Quarter 2021 Financial Results and Business Highlights

Exhibit 99.1 Biomea Fusion Reports Third Quarter 2021 Financial Results and Business Highlights ? Announced FDA clearance of Investigational New Drug Application (IND) for BMF-219, the company?s first development candidate from the FUSION platform ? Phase I trial to enroll adult patients with relapsed or refractory acute leukemia, including those with an MLL/KMT2A gene rearrangement or NPM1 mutati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40335 Biomea Fusion, Inc.

Biomea Fusion Announces FDA Clearance of Investigational New Drug Application for Irreversible Menin Inhibitor BMF-219

Exhibit 99.1 Biomea Fusion Announces FDA Clearance of Investigational New Drug Application for Irreversible Menin Inhibitor BMF-219 ? Biomea Fusion to transform to a Clinical Stage Company with First in Human (FIH) Clinical Trial ? BMF-219 advances as the first clinical stage therapeutic from the company?s deep pipeline of covalent irreversible small molecules ? BMF-219 is a novel, first-in-class,

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2021 BIOMEA FUSION, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commission

- See attached for financial tables - BIOMEA FUSION, INC. Condensed Statement of Operations (in thousands, except share and per share amounts)

Exhibit 99.1 Biomea Fusion Reports Second Quarter 2021 Financial Results and Business Highlights ? Completed investigational new drug (?IND?) enabling studies for lead program, BMF-219, an irreversibly binding menin inhibitor. On track to complete IND submission for Phase I/II study of BMF-219 as treatment for patients with menin-dependent acute myeloid leukemia (?AML?) and acute lymphocytic leuke

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40335 Biomea Fusion, Inc.

Employment Offer Letter Agreement by and between the Registrant and Franco Valle

Exhibit 10.2 May 11, 2021 Franco Valle [email protected] Dear Franco Valle, I am pleased to offer you employment with Biomea Fusion Inc. (the ?Company?). The purpose of this letter is to set forth the terms of your proposed employment with the Company. If you indicate your agreement to the terms in this letter by signing the last page, this letter will constitute your employment agreement wit

Transition and Separation Agreement by and between the Registrant and Sunny Lee Ryan

Exhibit 10.1 TRANSITION AND SEPARATION AGREEMENT This Transition and Separation Agreement (the "Agreement") by and between Sunny Lee Ryan ("Employee") and Biomea Fusion, Inc. (the "Company"), is made effective as of Employee's signature (the "Effective Date") with reference to the following facts: A. Employee is Executive Vice President of Finance pursuant to the terms of an Employment Agreement (

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Biomea Fusion, Inc. Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2021 Biomea Fusion, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commissio

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2021 BIOMEA FUSION, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commission File

Disclaimer and Forward-Looking Statement Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future financial performance of Biomea Fusion, Inc.

Exhibit 99.1 Corporate Presentation July 2021Exhibit 99.1 Corporate Presentation July 2021 Disclaimer and Forward-Looking Statement Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future financial performance of Biomea Fusion, Inc. (the ?Company?) and involve known and unknown risks, uncert

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2021 BIOMEA FUSION, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commission File

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2021 BIOMEA FUSION, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commission File N

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2021 BIOMEA FUSION, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commission File

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2021 BIOMEA FUSION, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commission File

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Biomea Fusion, Inc. Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2021 Biomea Fusion, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40335 82-2520134 (State or Other Jurisdiction of Incorporation) (Commission F

Exhibit 4.4

Exhibit 4.4 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary describes our capital stock and the material provisions of our amended and restated certificate of incorporation and our amended and restated bylaws, the investors? rights agreement to which we and certain of our stockholders are parties and of the Delaw

Biomea Fusion Reports First Quarter 2021 Financial Results and Business Highlights -- Received $167 million in aggregate gross proceeds in April from initial public offering -- – Advancing lead oncology program BMF-219, a small molecule irreversible

Exhibit 99.1 Biomea Fusion Reports First Quarter 2021 Financial Results and Business Highlights - Received $167 million in aggregate gross proceeds in April from initial public offering - ? Advancing lead oncology program BMF-219, a small molecule irreversible menin inhibitor, toward IND filing in second half of 2021 - - Mick Hitchcock, Ph.D., former senior advisor to Gilead joined the Board of Di

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40335 Biomea Fusion, Inc.

JOINT FILING AGREEMENT

Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G with respect to the common stock of Biomea Fusion, Inc.

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of April 30, 2021, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare Fund III, LP, Cormorant Private Healthcare GP III, LLC, Cormorant Asset Management, LP and Bihua Chen (collectively, the ?Filers?). Each of the Filers may be required to file with

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ___)* Biomea Fusion, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09077A106 (CUSIP Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Biomea Fusion, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09077A106 (CUSIP Number) Neb Obradovic Cormorant Asset Management, L.P. 200 Clarendon Street, 52nd Floor Boston, MA 02116 Tel. No.: 857-702-0386 (Name, Address and Telephone

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Biomea Fusion, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securit

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Biomea Fusion, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 09077A106 (CUSIP Number) April 20, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the

Amended and Restated Bylaws.

Exhibit 3.4 Amended and Restated Bylaws of Biomea Fusion, Inc. (a Delaware corporation) Table of Contents Page Article I - Corporate Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 Article II - Meetings of Stockholders 1 2.1 Place of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Notice of Business to be Brought Before a Meeting 2 2.6 Additional Requirements For Valid Nomination o

- S-8

As filed with the Securities and Exchange Commission on April 20, 2021 Registration No.

Biomea Announces Closing of Initial Public Offering

EX-99.1 Exhibit 99.1 Biomea Announces Closing of Initial Public Offering Redwood City, California, April 20, 2021 – Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers, today announced the closing of its initial publ

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2021 BIOMEA FUSION, INC. (Exact name of registrant as specified in its charter) Delaware 001-40335 82-2520134 (State or other jurisdiction of incorporation) (Commission File

Amended and Restated Certificate of Incorporation.

Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BIOMEA FUSION, INC. Biomea Fusion, Inc. (the ?Corporation?), a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify as follows: 1. The name of the Corporation is Biomea Fusion, Inc. The Corporation was incorporated by the filing of its original Certificate of

Fig. 1. Persistent site occupancy of a marketed irreversible inhibitor observed in the absence of sustained drug exposure.

Table of Contents Filed pursuant to Rule 424(b)(4) Registration Nos. 333-254793 and 255271 9,000,000 shares Common stock This is an initial public offering of shares of common stock of Biomea Fusion, Inc. We are offering 9,000,000 shares of our common stock to be sold in the offering. The initial public offering price is $17.00 per share of common stock. Prior to this offering, there has been no p

- S-1MEF

As filed with the Securities and Exchange Commission on April 15, 2021 Registration No.

* * *

140 Scott Drive Menlo Park, California 94025 Tel: +1.650.328.4600 Fax: +1.650.463.2600 www.lw.com FIRM / AFFILIATE OFFICES April 15, 2021 Beijing Boston Brussels Century City Chicago Dubai D?sseldorf Frankfurt Hamburg Hong Kong Houston London Los Angeles Madrid Milan Moscow Munich New York Orange County Paris Riyadh San Diego San Francisco Seoul Shanghai Silicon Valley Singapore Tokyo Washington,

- S-1/A

Table of Contents As filed with the Securities and Exchange Commission on April 15, 2021.

Form 8-A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOMEA FUSION, INC. (Exact name of registrant as specified in its charter) Delaware 11-3430072 (State of incorporation or organization) (I.R.S. Employer Identification No.) 726 Main Street Redwoo

Biomea Fusion, Inc. 726 Main Street Redwood City, California 94063

Biomea Fusion, Inc. 726 Main Street Redwood City, California 94063 April 13, 2021 VIA EDGAR AND E-MAIL United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Ada D. Sarmento and Dillon Hagius Re: Biomea Fusion, Inc. Registration Statement on Form S-1 (Registration No. 333-254793) Ladies and

[Signature page follows]

April 13, 2021 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

Form of Common Stock Certificate.

Exhibit 4.2 BF CUSIP 09077A 10 6 INCORPORATED UNDER THE LAWS OF THE STATE SEE REVERSE FOR CERTAIN OF DELAWARE DEFINITIONS AND LEGENDS This certifies that BY: AMERICAN COUNTERSIGNED is the record holder of STOCK AND FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $0.0001 PAR VALUE PER SHARE, OF (BROOKLYN, BIOMEA FUSION, INC. TRANSFER transferable on the books of the Corporation in person or by

Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the 2021 Incentive Award Plan

Exhibit 10.4(c) BIOMEA FUSION, INC. 2021 INCENTIVE AWARD PLAN RESTRICTED STOCK AWARD GRANT NOTICE Biomea Fusion, Inc., a Delaware corporation, (the ?Company?), pursuant to its 2021 Incentive Award Plan, as amended from time to time (the ?Plan?), hereby grants to the holder listed below (?Participant?) the number of shares of the Company?s Common Stock set forth below (the ?Shares?) subject to all

Non-Employee Director Compensation Program

Exhibit 10.9 BIOMEA FUSION, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM This Biomea Fusion, Inc. (the ?Company?) Non-Employee Director Compensation Program (this ?Program?) has been adopted under the Company?s 2021 Incentive Award Plan (the ?Plan?) and shall be effective as of the closing of the Company?s initial public offering of its common stock (the ?Effective Date?). Capitalized terms not

Form of Amended and Restated Bylaws, to be in effect immediately prior to the completion of this offering

Table of Contents Exhibit 3.4 Amended and Restated Bylaws of Biomea Fusion, Inc. (a Delaware corporation) Table of Contents Table of Contents Page Article I - Corporate Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 Article II - Meetings of Stockholders 1 2.1 Place of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Notice of Business to be Brought Before a Meeting 2 2.6 Additional

Form Executive Change in Control and Severance Agreement

Exhibit 10.11 BIOMEA FUSION, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the ?Agreement?) is made and entered into by and between [] (?Executive?) and Biomea Fusion, Inc. (the ?Company?), effective as of [the latest date set forth by the signatures of the parties hereto below]/[the date Executive commences employment with the Company] (the ?Effect

- S-1/A

Table of Contents As filed with the Securities and Exchange Commission on April 12, 2021.

2021 Employee Stock Purchase Plan.

Exhibit 10.5 BIOMEA FUSION, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN ARTICLE 1 PURPOSE The Plan?s purpose is to assist employees of the Company and its Designated Subsidiaries in acquiring a stock ownership interest in the Company, and to help such employees provide for their future security and to encourage them to remain in the employment of the Company and its Subsidiaries. The Plan consists of t

Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2021 Incentive Award Plan

Exhibit 10.4(d) BIOMEA FUSION, INC. 2021 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Biomea Fusion, Inc., a Delaware corporation, (the ?Company?), pursuant to its 2021 Incentive Award Plan, as amended from time to time (the ?Plan?), hereby grants to the holder listed below (?Participant?), an award of restricted stock units (?Restricted Stock Units? or ?RSUs?). Each vested Restri

* * *

140 Scott Drive Menlo Park, California 94025 Tel: +1.650.328.4600 Fax: +1.650.463.2600 www.lw.com FIRM / AFFILIATE OFFICES April 12, 2021 Beijing Boston Brussels Century City Chicago Dubai D?sseldorf Frankfurt Hamburg Hong Kong Houston London Los Angeles Madrid Milan Moscow Munich New York Orange County Paris Riyadh San Diego San Francisco Seoul Shanghai Silicon Valley Singapore Tokyo Washington,

Form of Underwriting Agreement

Exhibit 1.1 Biomea Fusion, Inc. [?] Shares of Common Stock, par value $0.0001 per share Underwriting Agreement [?], 2021 J.P. Morgan Securities LLC Jefferies LLC Piper Sandler & Co. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 c/o Jefferies LLC 520 Madison Avenue New York, NY 10022 c/o Piper Sandler

Amended and Restated Certificate of Incorporation, as amended, currently in effect

Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BIOMEA FUSION, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Biomea Fusion, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HEREBY CERTIFY: 1. That the name o

Form of Stock Award Grant Notice and Stock Award Agreement under the 2021 Incentive Award Plan.

Exhibit 10.4(b) BIOMEA FUSION, INC. 2021 INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE Biomea Fusion, Inc., a Delaware corporation, (the ?Company?), pursuant to its 2021 Incentive Award Plan, as may be amended from time to time (the ?Plan?), hereby grants to the holder listed below (?Participant?), an option to purchase the number of shares of the Company?s Common Stock (the ?Shares?), set forth

Form of Indemnification and Advancement Agreement for Directors and Officers

Exhibit 10.10 INDEMNIFICATION AND ADVANCEMENT AGREEMENT This Indemnification and Advancement Agreement (?Agreement?) is made as of [ ? ], 20[ ? ] by and between Biomea Fusion, Inc., a Delaware corporation (the ?Company?), and , [a member of the Board of Directors/an officer/an employee/an agent/a fiduciary] of the Company (?Indemnitee?). This Agreement supersedes and replaces any and all previous

2021 Incentive Award Plan

Exhibit 10.4(a) BIOMEA FUSION, INC. 2021 INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan?s purpose is to enhance the Company?s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. ARTICLE II. DEFINITIONS As used in the Plan, the following words and phrases have

Form of Amended and Restated Certificate of Incorporation, to be in effect immediately prior to the completion of this offering

Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BIOMEA FUSION, INC. Biomea Fusion, Inc. (the ?Corporation?), a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify as follows: 1. The name of the Corporation is Biomea Fusion, Inc. The Corporation was incorporated by the filing of its original Certificate of

Secondary Sublease, dated August 18, 2020, by and between the Registrant and Interactive Memories, Inc. d/b/a Mixbook

Exhibit 10.2 SECONDARY SUBLEASE This Secondary Sublease (?Secondary Sublease?), dated for reference purposes only as of August 18, 2020, is made by and between Interactive Memories, Inc. d/b/a Mixbook, a Delaware corporation (?Mixbook?) and Biomea Fusion, LLC, a Delaware limited liability company (?Biomea Fusion?) (collectively the ?Parties,? or individually a ?Party?). RECITALS A. Experticity, In

2020 Equity Incentive Plan

Exhibit 10.3(a) BIOMEA FUSION, INC. 2020 EQUITY INCENTIVE PLAN As Adopted December 18, 2020 1. Purpose. The purpose of the Plan is to advance the interests of the Company?s stockholders by enhancing the Company?s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing such persons with equity ownership opportunities and